Subscribe

Articles

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma
Multiple Myeloma
2021 Year in Review - Multiple Myeloma
A simulation modeling that incorporated clinically representative sequences for patients with transplant-ineligible NDMM and included attrition rates supports using the D-Rd regimen in the first-line setting instead of reserving it for later lines of therapy. Read More ›
Subgroup Analysis of the FORTE Study by Risk Categories of Carfilzomib-Based Induction/Consolidation with or without Autologous Transplant and Lenalidomide or Carfilzomib-Lenalidomide Maintenance
Multiple Myeloma
2021 Year in Review - Multiple Myeloma
A subgroup analysis of the FORTE study found that carfilzomib-lenalidomide-dexamethasone induction/consolidation (KRd) plus ASCT and carfilzomib-lenalidomide maintenance provided survival benefit to patients of all cytogenetic risk groups, including patients at high risk. Read More ›
Phase 1b TRIMM-2 Trial Results for Subcutaneous Talquetamab plus Daratumumab in Patients with RRMM
Multiple Myeloma
2021 Year in Review - Multiple Myeloma
Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talqueta­mab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination. Read More ›
Current Selective KRAS G12C Therapies in Non–Small-Cell Lung Cancer and Future Direction for Research
Lung Cancer
Web Exclusives
The chemistry behind selective KRAS G12C therapies and potential future research avenues were discussed in a recently released journal article. Read More ›
Assessing Factors Predictive of Pneumonitis Development with Use of Targeted Therapies in Non–Small-Cell Lung Cancer
Lung Cancer
Web Exclusives
In a recent study, researchers identified several factors associated with the development of pneumonitis with therapies targeting non–small-cell lung cancer. Read More ›
Best Selection of Line Therapy in Non–Small-Cell Lung Cancer without Genetic Alterations
Lung Cancer
Web Exclusives
Considerations in first-line and second-line therapy selection in non–small-cell lung cancer without genetic alterations were presented in a recent review article. Read More ›
Immune Checkpoint Inhibitor Use in Non–Small-Cell Lung Cancer Causes Primarily Mild Adverse Events
Lung Cancer
Web Exclusives
Although generally mild adverse events are associated with the use of immune checkpoint inhibitors for non–small-cell lung cancer, occasionally serious complications may result. Read More ›
From The Editors February 2022
From The Editors February 2022
From the Editor
TON - February 2022 Vol 15, No 1
The February issue of The Oncology Nurse-APN/PA (TON) features a variety of articles that specifically address topics of interest for nurses, navigators, and advanced practice providers caring for patients with cancer, including the latest results from clinical trials evaluating novel and FDA-approved therapies being used to extend survival and enhance quality of life. Read More ›
Advocacy Update: Innovation Remains Key to Providing Services for Patients with Cancer
Patient Advocacy, AVBCC Summit Highlights
TON - February 2022 Vol 15, No 1
As the COVID-19 pandemic continues into 2022, advocacy groups have worked tirelessly to provide vital services to patients with cancer while facing numerous challenges, including reductions in staff and decreased funding. Read More ›
CAR T-Cell Therapies May Improve Outcomes in Relapsed/Refractory Large B-Cell Lymphoma
ASH, Lymphoma
TON - February 2022 Vol 15, No 1
The results from 2 phase 3 clinical trials highlighted the superiority of CAR T-cell therapies over current standard of care (SOC) when used earlier in the course of treatment for patients with large B-cell lymphoma (LBCL). Read More ›

Page 47 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.